[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lupus-glomerulonephritis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":207,"states":223},"Lupus Glomerulonephritis",32,27,[8,16,22,29,36,42,48,54,60,67,73,79,85,92,98,104,110,116,122,128,134,139,145,151,157,163,169,175,182,188,194,200],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)",[12],"Phase 2","RECRUITING","2026-08-26T02:15:42.447052Z","2026-07-05T05:32:16.729991Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07015983","A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)",[12],"2026-08-03T00:59:52.468532Z","2026-07-05T05:32:16.725542Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07611214","PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis",[26],"Phase 4","2026-08-26T02:17:06.985283Z","2026-05-29T15:36:40.229463Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06121297","RESET-SLE: A Phase 1\u002F2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",[33],"Phase 1\u002FPhase 2","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:29.164988Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06897930","A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE",[33],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.793672Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06581198","A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE\u002FLN)",[12],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.728724Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05538208","The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study",[12],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:28.346433Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05039619","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:27.957517Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT06975787","Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis",[64],"Phase 1","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.859952Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07225387","Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial",[26],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:27.813070Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05201469","VIBRANT: VIB4920 for Active Lupus Nephritis",[12],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:27.278666Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":71,"content_modified":84},"NCT07201129","A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment",[83],"Phase 3","2026-05-05T02:43:26.964978Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT07107659","Safety and Efficacy of ONT01 in Lupus",[89],"Early Phase 1","2026-08-26T02:18:06.247899Z","2026-05-05T02:35:31.927773Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT07323524","Dapagliflozin in Active Lupus Nephritis",[26],"2026-08-26T02:18:03.638950Z","2026-05-05T02:35:31.746503Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus",[33],"2026-08-26T02:17:20.511551Z","2026-05-05T02:35:31.669019Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT06557265","A Phase 1\u002F2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)",[33],"2026-08-26T02:18:58.958025Z","2026-06-17T02:29:30.003977Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[33],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06217107","Wellness & Workforce Solution for Lupus\u002FLupus Nephritis",[],"2026-08-26T02:19:09.651016Z","2026-07-30T01:46:14.439043Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06711887","Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)",[83],"2026-08-26T02:18:13.438956Z","2026-07-19T19:36:05.133384Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT00001372","Study of Systemic Lupus Erythematosus",[],"2026-08-26T02:19:16.454910Z","2026-07-05T18:42:10.720140Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":46,"content_modified":138},"NCT06527872","Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN",[],"2026-05-13T02:55:06.498265Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06708845","US Zamto-cel Autoimmune Diseases",[64],"2026-08-26T02:17:16.980188Z","2026-06-14T18:39:22.236937Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06927219","Research Accelerated by You Lupus Registry",[],"2026-08-26T02:15:13.282904Z","2026-05-13T02:55:06.591214Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05934149","Lupus Landmark Study: A Prospective Registry and Biorepository",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.394638Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.700539Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT01802034","Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)",[],"2026-08-26T02:16:49.565137Z","2026-05-13T02:55:06.077698Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT00001979","Immune System Related Kidney Disease",[],"2026-08-26T02:18:24.494016Z","2026-05-13T02:55:06.026172Z",{"nct_id":176,"title":177,"phases":178,"status":179,"updated_at":180,"content_modified":181},"NCT06984341","A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",[64],"NOT_YET_RECRUITING","2026-08-03T02:51:12.602181Z","2026-05-05T02:43:29.728328Z",{"nct_id":183,"title":184,"phases":185,"status":186,"updated_at":34,"content_modified":187},"NCT06518668","A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus",[64],"ENROLLING_BY_INVITATION","2026-07-05T03:45:20.249630Z",{"nct_id":189,"title":190,"phases":191,"status":186,"updated_at":192,"content_modified":193},"NCT07038447","A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",[64],"2026-08-26T02:15:11.740957Z","2026-06-16T05:54:07.853790Z",{"nct_id":195,"title":196,"phases":197,"status":186,"updated_at":198,"content_modified":199},"NCT06375993","A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease",[64],"2026-08-26T02:16:24.970704Z","2026-06-16T05:54:07.753503Z",{"nct_id":201,"title":202,"phases":203,"status":204,"updated_at":205,"content_modified":206},"NCT05126277","Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis",[83],"ACTIVE_NOT_RECRUITING","2026-08-03T02:57:18.103669Z","2026-05-05T02:43:28.648499Z",[208,212,216,220],{"biomarker":209,"count":210,"slug":211},"Anti-ds DNA Antibody",8,"anti-ds-dna-antibody",{"biomarker":213,"count":214,"slug":215},"Antinuclear Antibody",7,"antinuclear-antibody",{"biomarker":217,"count":218,"slug":219},"anti-Smith",3,"anti-smith",{"biomarker":221,"count":218,"slug":222},"CD19 Gene","cd19-gene",[224,228,232,236,240,244,247,250,253,256,259,263,266,270,273,276,279,283,286,289,292,295,298],{"state":225,"count":226,"slug":227},"New York",17,"new-york",{"state":229,"count":230,"slug":231},"Texas",14,"texas",{"state":233,"count":234,"slug":235},"California",13,"california",{"state":237,"count":238,"slug":239},"Georgia",12,"georgia",{"state":241,"count":242,"slug":243},"Florida",10,"florida",{"state":245,"count":210,"slug":246},"North Carolina","north-carolina",{"state":248,"count":214,"slug":249},"Illinois","illinois",{"state":251,"count":214,"slug":252},"Massachusetts","massachusetts",{"state":254,"count":214,"slug":255},"Ohio","ohio",{"state":257,"count":214,"slug":258},"Pennsylvania","pennsylvania",{"state":260,"count":261,"slug":262},"Colorado",6,"colorado",{"state":264,"count":261,"slug":265},"Missouri","missouri",{"state":267,"count":268,"slug":269},"Louisiana",5,"louisiana",{"state":271,"count":268,"slug":272},"Maryland","maryland",{"state":274,"count":268,"slug":275},"Michigan","michigan",{"state":277,"count":268,"slug":278},"New Jersey","new-jersey",{"state":280,"count":281,"slug":282},"Alabama",4,"alabama",{"state":284,"count":281,"slug":285},"Tennessee","tennessee",{"state":287,"count":218,"slug":288},"Arizona","arizona",{"state":290,"count":218,"slug":291},"Minnesota","minnesota",{"state":293,"count":218,"slug":294},"South Carolina","south-carolina",{"state":296,"count":218,"slug":297},"Washington","washington",{"state":299,"count":218,"slug":300},"Wisconsin","wisconsin"]